Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults

Condition(s) studied

Study summary

The main aim of the study is to assess real-world effectiveness of nemolizumab in Atopic Dermatitis (AD) as measured by physician assessment and patient reported outcome (PRO) in clinical practice at Month 6.

Eligibility

Primary outcome measure(s)

• Investigator Global Assessment (IGA) at Month 6 — At Month 6
  The IGA is a 5-point scale ranging from 0 (clear) to 4 (severe) used by the investigator or trained designee to evaluate the global severity of AD and the clinical response to a treatment.
• Peak Pruritus Numerical Rating Scale (PP NRS) at Month 6 — At Month 6
  The PP NRS is a single question validated PRO assessment that participants will use to report the maximum intensity of their pruritus (itch). The PP NRS consists of the following question: "On a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable', how would you rate your itch at the worst moment during the previous 24 hours?". Here, a lower score indicates a better outcome.

Trial sites (108)

+ 68 more sites — see the full list on the official registry below.

More Galderma R&D trials in the UK

Other trials for the same condition